Burlington Stores Inc vs Novavax Inc — how do they compare? Burlington Stores Inc trades at $354.86 (market cap $22.59B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Burlington Stores Inc is far larger — about 17.2× Novavax Inc's market cap, and Burlington Stores Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| BURL | NVAX | |
|---|---|---|
Market Cap | $22.59B | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $372.19 | $11.19 |
52-Week Low | $242.43 | $6.22 |
Enterprise Value | $27.71B | $889.30M |
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $353.63, down 4.81% in the last session but maintains strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock shows a bullish technical setup with key support at $346 and resistance at $365, while fundamentals reveal impressive profitability with 39.14% ROE and expanding margins. Recent news highlights the company's successful smaller-store strategy and upward revised 2026 outlook.
BURL presents a compelling growth opportunity with 94% analyst buy ratings and a $367 consensus target offering 3.8% upside. However, elevated valuation multiples (P/E 36.92) and competitive retail pressures warrant caution. The company's debt-to-asset ratio rising to 20.99% in 2026 and recent insider selling of $619,200 worth of shares represent notable risk factors for investors.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Trailing returns across standard periods
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →